Tau: A Novel Entry Point for mTOR-Based Treatments in Autism Spectrum Disorder?
- PMID: 32380047
- DOI: 10.1016/j.neuron.2020.04.019
Tau: A Novel Entry Point for mTOR-Based Treatments in Autism Spectrum Disorder?
Abstract
Dysregulation of the PI3K/Akt/mTOR pathway has become a point of convergence in autism spectrum disorder (ASD). In this issue of Neuron, Tai et al. (2020) identify a therapeutic role for tau reduction in downregulating this pathway and ameliorating ASD-like symptoms.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Interests Mustafa Sahin reports grant support from Novartis, Roche, Pfizer, Ipsen, LAM Therapeutics, and Quadrant Biosciences. He has served on scientific advisory boards for Sage, Roche, Celgene, Aeovian, Regenxbio, and Takeda.
Comment on
-
Tau Reduction Prevents Key Features of Autism in Mouse Models.Neuron. 2020 May 6;106(3):421-437.e11. doi: 10.1016/j.neuron.2020.01.038. Epub 2020 Mar 2. Neuron. 2020. PMID: 32126198 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous